Regulatory approval
Published by the Health Service Executive. Approved
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.
This is written in the approval document.
Reimbursement
Hospital
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | HER2-negative | Invasive Breast Carcinoma | Bevacizumab, Paclitaxel |